- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04155710
Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLL
A Phase 1/2 Study Evaluating the Safety and Efficacy of IOV-2001 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Study Overview
Status
Intervention / Treatment
Detailed Description
This study involves patients receiving nonmyeloablative (NMA) lymphocyte depleting (LD) preparative regimen prior to infusion of IOV-2001 followed by IL-2 administration.
In Phase 1, patients meeting the eligibility criteria will be enrolled and will receive treatment with IOV-2001 followed by low dose IL-2 or high dose IL-2.
After completion of Phase 1, the recommended Phase 2 dose (RP2D) will be evaluated in selected patient cohorts defined in the Phase 2 part of the study.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Iovance Biotherapeutics Clinical Inquiries
- Phone Number: 866.565.4410
- Email: Clinical.Inquiries@iovance.com
Study Locations
-
-
Florida
-
Tampa, Florida, United States, 33612
- Recruiting
- Moffitt Cancer Center
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Recruiting
- Duke University
-
-
Ohio
-
Cincinnati, Ohio, United States, 45219
- Recruiting
- University of Cincinnati Medical Center
-
Columbus, Ohio, United States, 43210
- Recruiting
- Ohio State University
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15224
- Recruiting
- Allegheny Health
-
-
Tennessee
-
Memphis, Tennessee, United States, 38120
- Withdrawn
- Baptist Cancer Center
-
-
Utah
-
Salt Lake City, Utah, United States, 84112
- Withdrawn
- University of Utah, Huntsman Cancer Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Patients with CLL or SLL with radiographically measurable disease
- Cohort 2 only: patients with progressed or progressing CLL/SLL on ibrutinib or acalabrutinib with del 17p and/or TP53 mutated
- Cohort 3 only: patients with progressed or progressing CLL/SLL on ibrutinib or acalabrutinib without del 17p and/or TP53 mutated
- Patients must have documented progression or be progressing on ibrutinib or acalabrutinib, as indicated by the presence of known BTK resistance mutation
Patients must have received at least 1 prior regimen (only for patients without del 17p and/or TP53 mutated) and currently be on ibrutinib or acalabrutinib. For patients on combination therapy as the last line of therapy prior study entry, progression to any of the individual components of the combination therapy, rather than to the combination regimen, is required.
- For Cohort 2: The single prior regimen can be ibrutinib or acalabrutinib (ie, patients are eligible while progressing on their first line of therapy)
- For Cohort 3: Patients must have progressed on at least 1 additional line of therapy in addition to ibrutinib or acalabrutinib
- Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and an estimated life expectancy of ≥ 3 months.
- Patients must have adequate bone marrow function to receive NMA-LD
- Pulmonary function assessed by spirometry demonstrating FEV1 > 50% predicted normal
- Cardiac function demonstrating left ventricular ejection fraction (LVEF) > 45%
- Patients of childbearing potential or their partners of childbearing potential must be willing to practice an approved method of birth control during treatment and for 12 months after receiving the last protocol-related therapy.
Exclusion Criteria:
- Patients who have received an organ allograft or prior cell transfer therapy within 20 years.
- Patients with known or suspected transformed disease (ie, Richter's Transformation).
- Patients who received treatment with any systemic chemotherapy, immunotherapy, targeted small molecule inhibitors, or other biologic agents within 30 days or 5 half-lives, whichever is shorter, of IOV-2001 infusion with the exception of ibrutinib or acalabrutinib
- Patients with known involvement of central nervous system (CNS) by lymphoma or leukemia
- Patients who are on chronic systemic steroid therapy >5 mg/day prednisone equivalent for any reason
- Patients who have active systemic infections requiring systemic ABX, autoimmune anemia or thrombocytopenia, coagulation disorders, or other active major medical illnesses of the cardiovascular, respiratory, or immune system.
Patients who are seropositive for any of the following:
- Human immunodeficiency virus (HIV)-1 or HIV-2 antibodies
- Hepatitis B antigen (HbsAg) or anti-hepatitis B core total antibodies (anti-HbcAb), or hepatitis C antibody (HCVAb)
- Patients with active and chronic fungal, bacterial, or viral infection requiring IV treatment
- Patients who require treatment for anti-coagulation with a vitamin K antagonist (warfarin)
- Patients who have received a live or attenuated vaccine within 28 days of beginning the preparative NMA-LD regimen
- Patients who are pregnant or breastfeeding
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort 1a
CLL/SLL patients whose disease has relapsed or is relapsing post ibrutinib or acalabrutinib therapy.
Patients will receive IOV-2001 + low dose IL-2.
|
Adoptive cell therapy (ACT) manufactured from peripheral blood lymphocytes (PBL).
The final investigational product is a cryopreserved cell suspension.
Other Names:
6 doses of subcutaneous (SC) LD-IL-2 (9 MIU every 8-12 hours) will follow the infusion of IOV-2001
Other Names:
|
Experimental: Cohort 1b
CLL/SLL patients whose disease has relapsed or is relapsing post ibrutinib or acalabrutinib therapy.
Patients will receive IOV-2001 + high dose IL-2.
|
Adoptive cell therapy (ACT) manufactured from peripheral blood lymphocytes (PBL).
The final investigational product is a cryopreserved cell suspension.
Other Names:
6 doses of IV HD-IL-2 (600,000 IU/kg Q8-12H will follow the infusion of IOV-2001
Other Names:
|
Experimental: Cohort 2
CLL/SLL patients with del 17p who progressed or are progressing on ibrutinib or acalabrutinib therapy.
Patients will receive IOV-2001 + IL-2.
|
Adoptive cell therapy (ACT) manufactured from peripheral blood lymphocytes (PBL).
The final investigational product is a cryopreserved cell suspension.
Other Names:
6 doses of IL-2 will follow the infusion of IOV-2001
Other Names:
|
Experimental: Cohort 3
CLL/SLL patients without del 17p who progressed or progressing on ibrutinib or acalabrutinib therapy.
Patients will receive IOV-2001 + IL-2.
|
Adoptive cell therapy (ACT) manufactured from peripheral blood lymphocytes (PBL).
The final investigational product is a cryopreserved cell suspension.
Other Names:
6 doses of IL-2 will follow the infusion of IOV-2001
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Phase I: RP2D (Recommended Phase 2 Dose)
Time Frame: up to one year or depending on when the recommended phase 2 dose is determined
|
to determine the recommended Phase 2 dose of IOV-2001 followed by interleukin-2 (IL-2)
|
up to one year or depending on when the recommended phase 2 dose is determined
|
Phase 2: Objective Response Rate
Time Frame: up to two years
|
To evaluate efficacy of the RP2D of IOV-2001 followed by IL-2 as measured by objective response rate (ORR) per investigator assessment
|
up to two years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Phase 1: Adverse Events
Time Frame: up to one year or depending on when the recommended phase 2 dose is determined
|
Incidence of adverse events (AEs) and serious AEs
|
up to one year or depending on when the recommended phase 2 dose is determined
|
Phase 1: Disease Assessment
Time Frame: up to two years
|
To assess the evidence of activity of IOV-2001 followed by IL-2 as measured by ORR per Investigator assessment
|
up to two years
|
Phase 1: Disease Assessment
Time Frame: up to two years
|
To assess CR/CRi rate per Investigator as defined by International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2018 criteria for IOV-2001 followed by IL-2
|
up to two years
|
Phase 1: Disease Assessment
Time Frame: up to two years
|
To assess minimum residual disease (MRD)-negative rate for IOV-2001 followed by IL-2
|
up to two years
|
Phase 2: Disease Assessment (Separately for each cohort)
Time Frame: up to two years
|
To assess progression free survival (PFS) of IOV-2001 therapy followed by IL-2
|
up to two years
|
Phase 2: Disease Assessment (Separately for each cohort)
Time Frame: up to two years
|
To assess overall survival (OS) of IOV-2001 therapy followed by IL-2
|
up to two years
|
Phase 2: Disease Assessment (Separately for each cohort)
Time Frame: up to two years
|
To assess duration of response (DOR) of IOV-2001 therapy followed by IL-2
|
up to two years
|
Phase 2: Disease Assessment (Separately for each cohort)
Time Frame: up to two years
|
To assess disease control rate (DCR) of IOV-2001 therapy followed by IL-2
|
up to two years
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Iovance Biotherapeutics Medical Monitor, Iovance Biotherapeutics, Inc.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Leukemia, B-Cell
- Lymphoma
- Leukemia
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Lymphoid
- Physiological Effects of Drugs
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Analgesics, Non-Narcotic
- Antineoplastic Agents
- Interleukin-2
Other Study ID Numbers
- IOV-CLL-01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Lymphocytic Leukemia
-
National Heart, Lung, and Blood Institute (NHLBI)Active, not recruitingLeukemia, Lymphocytic, Chronic, B-Cell | Chronic Lymphocytic Leukemia | Leukemia, Chronic Lymphatic | B-Cell Chronic Lymphocytic Leukemia | Leukemia, Lymphocytic, Chronic | B-Lymphocytic Leukemia, Chronic | Leukemia, Chronic Lymphocytic, B-Cell | Lymphocytic Leukemia, Chronic, B Cell | Lymphocytic Leukemia...United States
-
National Cancer Institute (NCI)CompletedB-cell Chronic Lymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic LeukemiaUnited States
-
National Cancer Institute (NCI)TerminatedRefractory Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic LeukemiaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedB-cell Chronic Lymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia | Stage 0 Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic LeukemiaUnited States
-
National Cancer Institute (NCI)CompletedB-cell Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic LeukemiaUnited States
-
National Cancer Institute (NCI)TerminatedLeukemia | B-cell Chronic Lymphocytic Leukemia | Prolymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic LeukemiaUnited States
-
OHSU Knight Cancer InstituteOregon Health and Science UniversityCompletedRefractory Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic LeukemiaUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); Celgene CorporationTerminatedChronic Lymphocytic Leukemia | B-cell Chronic Lymphocytic Leukemia | Stage 0 Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic LeukemiaUnited States
-
Roswell Park Cancer InstituteWithdrawnRefractory Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic Leukemia
-
Mayo ClinicNational Cancer Institute (NCI)CompletedChronic Lymphocytic Leukemia | Stage III Small Lymphocytic Lymphoma | Stage IV Small Lymphocytic Lymphoma | Stage 0 Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage I Small Lymphocytic Lymphoma | Stage III Chronic Lymphocytic Leukemia and other conditionsUnited States
Clinical Trials on IOV-2001
-
Oryzon Genomics S.A.Alzheimer's Drug Discovery FoundationCompletedMild to Moderate Alzheimer's DiseaseUnited States
-
Intellia TherapeuticsRegeneron PharmaceuticalsRecruitingTransthyretin Amyloidosis (ATTR) With CardiomyopathyUnited States, Australia, United Kingdom, New Zealand
-
Intellia TherapeuticsActive, not recruitingTransthyretin-Related (ATTR) Familial Amyloid Cardiomyopathy | Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy | Wild-Type Transthyretin Cardiac AmyloidosisFrance, United Kingdom, New Zealand, Sweden
-
Oryzon Genomics S.A.CompletedBorderline Personality DisorderSpain, Serbia, United States, Germany, Bulgaria
-
Guangdong Hengrui Pharmaceutical Co., LtdRecruiting
-
Iovance Biotherapeutics, Inc.RecruitingMetastatic Melanoma | Unresectable Melanoma | Stage IV Non-small Cell Lung Cancer | Stage III Non-small Cell Lung CancerUnited States
-
Ichnos Sciences SANot yet recruitingRelapsed/Refractory Multiple MyelomaAustralia
-
BenevolentAI BioCompletedParkinson Disease | Excessive Daytime SleepinessUnited States
-
Centro de Estudios en Infectogía PediatricaWithdrawn
-
Alaunos TherapeuticsCompleted